跳至主要内容
临床试验/NCT05819385
NCT05819385招募中不适用

Ambispective, Non-Interventional Study to Evaluate the Epidemiology of Interstitial Lung Diseases (ILDs) Associated to Rheumatic Diseases (Rheumatoid Arthritis, Connective Tissue Diseases, Spondylarthritis and Sarcoidosis) and the Progression Risk Factors in the Mexican Population

Boehringer Ingelheim2 个研究点 分布在 1 个国家目标入组 312 人开始时间: 2025年6月18日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
312
试验地点
2
主要终点
Number of exacerbation per year (frequency of exacerbation)

研究概览

简要总结

This study aims to characterize the epidemiology of interstitial lung diseases (ILD) associated to connective tissue disease (CTD) in Mexico, and to study its correlation with the different comorbidities and treatments used, as well as the possible impacts of these factors on the outcome of progression, exacerbations, and mortality in patients with ILD associated to CTD.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Other

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • For newly data collection:
  • Male and female Patients.
  • Patients over 18 years old.
  • Patient who gives his/her signed informed consent to be able to use information about their condition.
  • Patient who has the diagnosis of: rheumatoid arthritis, connective tissue disease (CTD) (systemic sclerosis or scleroderma; inflammatory myopathy: antisynthetase, dermatomyositis, polymyositis, mixed connective tissue disease; systemic lupus erythematosus; primary Sjögren syndrome; pulmonary fibrosis associated with non-specific autoimmunity; primary systemic vasculitis; psoriasis, anchylosing spondylitis, reactive arthritis) Spondyloarthritis (SpA) or sarcoidosis, (accordingly with the updated clinical criteria for each pathology).
  • Patient with any interstitial lung diseases (ILD) diagnosed clinically and by a high-resolution computed tomography study with an interstitial pattern (supervised by an expert radiologist).
  • For existing data collection:
  • Medical Records from patients with whom contact was permanently lost for any reason since 2012 till the study start date.
  • Medical Records from male and female Patients.
  • Medical Records from patients over 18 years old.
  • Medical Records of patients that have at least: patient initials, date of birth, gender, date of diagnosis, full diagnosis of:
  • Patient who has the diagnosis of: rheumatoid arthritis, CTD (systemic sclerosis or scleroderma; inflammatory myopathy: antisynthetase, dermatomyositis, polymyositis, mixed connective tissue disease; Systemic lupus erythematosus; primary Sjögren syndrome; pulmonary fibrosis associated with non-specific autoimmunity; primary systemic vasculitis; psoriasis, anchylosing spondylitis, reactive arthritis) SpA or Sarcoidosis, (accordingly with the updated clinical criteria for each pathology).
  • Patient with any ILD diagnosed clinically and by a high-resolution computed tomography study with an interstitial pattern (supervised by an expert radiologist).

排除标准

  • Patient with a biopsy definition of usual interstitial pneumonitis, related to any other non-CTD.
  • Patient with post-chemotherapy or post-radiotherapy pneumonitis.
  • Medical Records of patients without full diagnostic of ILD (clinically and by biopsy or high-resolution computed tomography).

结局指标

主要结局

Number of exacerbation per year (frequency of exacerbation)

时间窗: up to 13 years

King's Brief Interstitial Lung Disease Questionnaire (K-BILD) score change over time

时间窗: up to 13 years

Time to first exacerbation: time in months elapsed until the first exacerbation from the diagnosis

时间窗: up to 13 years

Percent of pulmonary fibrosis: grade of parenchymal involvement evidenced by high-resolution computed tomography (HRCT)

时间窗: up to 13 years

Change in 6-minute walk tests (6-MWT) over time

时间窗: up to 13 years

Saint George Respiratory Questionnaire (SGRQ)-I score change over time

时间窗: up to 13 years

次要结局

  • Progression of pulmonary fibrosis by treatment received identified by HRCT patterns, lung function, activity score and damage index(up to 13 years)
  • Possibility to have an exacerbation and/or progression in pulmonary fibrosis, sorted by rheumatic disease type (rheumatoid arthritis (RA), connective tissue disease (CTD), spondyloarthritis (SpA) and Sarcoidosis)(up to 13 years)
  • Frequency of use of diagnostic tools (laboratory, cabinet)(up to 13 years)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验